Expression of the human GADD45a gene is increased in TK6 cells exposed to mutagens, clastogens and aneugens. It is known to be regulated through both p53-dependent and p53-independent pathways and WT1 has been implicated in both cases. This article reports an investigation into the effect that mutations in the WT1 and p53 response elements of the gene have on GADD45a expression. This was conducted in both p53 wild-type (TK6) and mutant (WI-L2-NS) human B lymphoblastoid cell lines. Gene expression was monitored using a GADD45a-green fluorescent protein reporter assay. Mutant cell lines were exposed to the mechanistically diverse genotoxins methyl methanesulphonate, cisplatin and mitomycin C (direct acting), hydroxyurea, aphidicolin and 5′fluorouracil (inhibitors of nucleotide/DNA synthesis) and benomyl (aneugen). In all cases, the induction of the reporter was reduced in the mutants compared with wild-type. These results provide experimental evidence for the implied role of WT1 in both p53-dependent and p53-independent pathways of GADD45a regulation and further insight into the mechanism of GADD45a induction by genotoxins.
Introduction
GADD45a is a p53-regulated, genotoxic stress-inducible gene. It is implicated in a number of key processes including control of cell cycle checkpoints and DNA repair processes through interactions with multiple proteins including Cdc2 protein kinase (1) , proliferating cell nuclear antigen (2), p21
Waf1/ Cip1 protein (3), core histone protein (4) and MTK/MEKK4 (5). GADD45a is regulated by both p53-dependent and p53-independent pathways depending on the stimulus although the response to ionising radiation is the only strictly p53-dependent pathway identified to date (6, 7) . p53 is required for the proper cellular response to genotoxic damage and its primary function is to act as a transcription factor (TF), activating or repressing target genes in response to DNA damage, as well as hypoxia and oncogene activation (7, 8) . DNA damage leads to the activation of DNA repair pathways and to apoptosis if damage is overwhelming (9, 10) . It is known that p53 plays a key role in cell cycle arrest and/or apoptosis in response to cellular stress and that it is involved in the regulation of GADD45a in response to DNA damage. In contrast to γ-radiation, most other causes of DNA damage can induce GADD45a in a p53-independent manner (11, 12) although p53 is still required for a maximal response (13, 14) .
GADD45a appears to be regulated directly by p53 through the p53 response element (RE) located in intron 3, where p53 protein binding can be detected after DNA damage (13) . It has been suggested that p53 is also able to affect the promoter of GADD45a, despite the lack of RE. The mechanism for this is unknown at present although WT1 is thought to be involved because it is able to both bind to the GADD45a promoter and to interact with p53 protein (13) . WT1 is a tumour suppressor involved in the development of Wilms' tumour in the kidney. It has four zinc-finger regions in the C-terminus, which are involved in binding, and activation and repression domains in the N-terminus. It has been proposed that the transcriptional activation/repression activity of WT1 is dependent on binding to a second TF and immunoprecipitation and transactivation assays suggest strongly that this is p53 (11) (12) (13) . WT1 protein has also been detected at the promoter of GADD45a (12, (15) (16) (17) (18) (19) . The human GADD45a gene contains GC-rich motifs within the promoter that match the consensus sequence for various TFs, including Egr1 and WT1 (20) . The Egr1-WT1 family of TFs defines a group of related proteins that have been associated with a variety of cellular processes, including stress response to mechanical injury for Egr1 and growth suppression for WT1 (13, 17, 21) .
This research was initiated to test the hypothesis that both the promoter WT1 RE and the p53 RE in intron 3 of the GADD45a gene are required for induction following exposure of TK6 cells to mechanistically diverse genotoxins. Expression of GADD45a was monitored using the GreenScreen HC assay, which exploits a green fluorescent protein (GFP) reporter containing the entire promoter region of the GADD45a gene and all the expressed RNA, except that the GFP gene replaces a similarly sized portion of the GADD45a gene, spanning exons 1 and most of exon 2 (22) . The reporter conserves spacing between the promoter WT1 and intron 3 p53 RE. The assay is widely used in the genotoxicity hazard screening of novel chemicals developed as pharmaceuticals, agrichemicals, flavours and fragrances, etc. Understanding GADD45a regulation is therefore important, as specific interference might lead to the generation of misleading positive or negative prediction of human hazard.
Novel, modified GFP reporter plasmids were constructed in which the WT1 and p53 REs were disabled by in vitro mutagenesis. These were then transfected into TK6 and WI-L2-NS cells and the novel cell lines investigated to discover the impact of disabling these REs on the expression of GADD45a after exposure to a range of genotoxins.
This work highlights the involvement of WT1 in GADD45a regulation and proposes a mechanism through which p53 is able to act on GADD45a at its promoter. The detrimental effect of mutated p53 can be seen very clearly and this emphasises the need for its competence in cell-based genotoxicity assays.
Materials and methods

Cell lines and plasmids
The p53 wild-type (wt) human B lymphoblastoid cell line TK6 and its sister p53 mutant cell line WI-L2-NS were purchased from the European collection of cell cultures. Both were derived from the parental line WI-L2. They differ in the organisation of the short arm of chromosome 17, on which the p53 gene is located. The WI-L2-NS p53 gene has a mutation at codon 237, which results in a change from methionine to isoleucine. Sequence analysis shows that GADD45a is wt in WI-L2-NS (23) .
Transfected cell lines were maintained in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated donor horse serum, 10 mM sodium pyruvate (Lonza Biologics, Slough, UK), 1.8 mM pen/strep and 200 mg/ml hygromycin B (catalogue no. 10687-010; Invitrogen, Paisley, UK) and kept at 37°C, 5% CO 2 and 95% humidity. p53 wt (TK6) and p53 mutant (WI-L2-NS) cells carrying the standard reporter and control plasmids were provided by the Walmsley laboratory strain collection.
GADD45a-GFP 'GreenScreen HC' assay protocol
The GADD45a-GFP GreenScreen HC assay protocol, data handling and decision thresholds were described in full by Hastwell et al. (22) . In brief, the assay utilises two TK6 strains, each carrying different reporter plasmids. The 'test' strain plasmid contains the intact GFP reporter plasmid, and the 'control' strain carries a control plasmid that has an extra base pair inserted next to the ATG start codon, which puts the GFP gene out of frame such that it is not expressed. The control strain allows the identification of fluorescent test compounds or compounds that induce cellular fluorescence that is not associated with changes in GADD45a expression: these would otherwise confound interpretation of data. Subtraction of fluorescence detected in the control strain from the test strain allows the interpretation of experimental data with low levels of non-GFP-derived fluorescence. Compounds that cause a statistically significant induction of fluorescence are designated genotoxic: this is defined as >3 times the standard deviation in the GFP signal from toxic and non-toxic non-genotoxins and is equivalent to a 1.5-fold increase over the vehicle-treated control. Data from compounds that produce a relative suspension growth <30% (compared with vehicle-treated controls) are rejected, as below this level, cell lysis confounds data analysis. In this study, all compounds were tested to 10 mM unless limited by solubility or toxicity.
Assays were performed using a standardised 96-well plate format in which four compounds were tested at nine 2-fold dilutions, along with various controls. The compounds were prepared as dictated by their aqueous solubility. Compounds with high aqueous solubility were dissolved directly in 2% dimethyl sulphoxide (DMSO) and diluted as necessary. Compounds with low aqueous solubility were dissolved in 100% DMSO to a stock concentration of 100 mM. Test solutions were then made by diluting in sterile distilled water. If the compound was still insoluble at this point, the stock concentration was further diluted with 100% DMSO. The water dilution step was then repeated to produce a fresh solution as required. The test samples were then serially diluted across the plate. An equal volume of cells in growth medium was then added to each well, halving the sample concentrations. The following in-plate controls were included as follows: 'low' (10 μg/ml) and 'high' (50 μg/ml) concentrations of MMS as positive controls; medium only, to detect contamination; diluent alone; diluent plus test sample to identify potentially interfering compound fluorescence or light absorbance. The MMS controls are in place for qualitative reasons and demonstrate that the assay is responding in a dose-dependent manner to toxic and genotoxic stress. The 'high' MMS standard must produce a fluorescence induction of at least 2, which must be greater than that from the 'low' MMS standard. The 'high' standard should reduce the final cell density <80% relative suspension growth (RSG), which must be a greater reduction than that in the 'low' standard (22) .
Cells from mid-passage were washed and resuspended at 2 × 10 6 cells/ml assay media. For each experiment, a parallel series of wells contained the control cell line, TK-GDCon, containing the out-of-frame GFP gene.
Plates were covered with a breathable membrane (Breath-Easy, Sigma), shaken gently for 30 s on a microplate shaker to mix the contents and then incubated without shaking at 37°C, 5% CO 2 and 95% humidity. After 48 h, fluorescence and absorbance data were collected (excitation 485 nm, emission 535 nm and absorbance 620 nm). The fluorescence data for each well are divided by the absorbance value to generate a 'brightness value', which distinguishes between a small number of highly fluorescent cells and a larger number of weakly fluorescent cells. In the figures, brightness is normalised to the untreated control, which therefore has a brightness of 1. The dose-dependent brightness data points depicted graphically are the means from four independent repeats. Error bars show standard error. The lowest concentration producing a brightness induction ≥1.5 is recorded as the lowest effect concentration (LEC).
Mutation of the p53 and WT1 RE in the plasmid-borne GADD45a gene
GADD45a gene sequences were excised from the GADD45a-GFP reporter plasmid and individual segments for modification were sub-cloned into pBluescript. Mutations were introduced in vitro (Stratagene Quikchange site-directed mutagenesis kit) and then recloned into the reporter plasmid. The DNA sequence of new plasmids was determined by sequence analysis (see Table I for original and altered sequences). New assay cell lines were created by transfecting these mutant reporter plasmids into p53 wt (TK6) and p53 mutant (WI-L2-NS) cell lines by electroporation. Electroporation conditions were as follows: 270 V at 960 μF using a Bio-Rad gene pulser II (Bio-Rad, Hemel Hempstead, UK). Three independent cell lines were produced for each mutant, and three transfectants from each transformation were taken forward for further study.
Results
The p53 wt (TK6) and p53 mutant (WI-L2-NS) cell lines containing the variously modified reporter constructs had comparable growth rates and constitutive levels of reporter expression. There were two exceptions: the TK6 and p53 mutant cells lines carrying the plasmid with a mutated WT1 RE. In these cells, basal reporter expression was significantly higher (24-34%; P < 0.05) than in either the unmutated or the p53 RE-mutated reporters although they were not significantly different to each other (P = 0.8). Because this altered constitutive expression was limited to just one plasmid and the differences between the plasmids are limited to just a few base pairs, the higher level of expression is more likely to be a consequence of the change in the regulation of reporter gene expression than a plasmid copy number or plasmid stability artefact. The dose-response GADD45a-GFP induction profiles produced from the cells carrying mutated reporter constructs varied quite markedly according to the nature of the genotoxic challenge. Table II shows the LECs for the compounds tested with the different reporters. The response with the WI-L2-NS-hosted reporters rarely crossed the 1.5-fold significance threshold. Figure 1 shows the induced fluorescence from TK6-hosted reporters (standard and p53-/WT1-mutated RE) in response to exposure to a number of different genotoxins. Fluorescence induction was greatest from the wt reporters: for reporters with a mutated p53 RE or WT1 RE, fluorescence induction was decreased. Because fluorescence induction is indicative of GADD45a reporter expression, it may be concluded that protein expression from the genomic GADD45a induction is also decreased when either the p53 or WT1 RE are mutated. Fluorescence induction in response to all genotoxic test compounds was greater in cells carrying the mutant WT1 RE than those carrying the mutant p53 RE, suggesting a more significant role for p53 than for WT1 in GADD45a regulation (Figure 1) .
None of the WI-L2-NS (p53 mutant) transfectants showed significant (≥1.5-fold) genotoxin-induced fluorescence. Mutation of the p53 RE and WT1 elements in the reporter plasmids in these cells did not have an effect on fluorescence induction (compared with that of the standard reporter in these cells). For example, Figure 2 shows fluorescence induction by cisplatin in the various WI-L2-NS reporters compared with induction in TK6 cells.
Discussion
These experiments were conceived to test the hypothesis that p53 regulation of GADD45a induction is mediated through the intron 3 RE and interaction with WT1 bound at its RE in the promoter. In addition, the interaction between mutant p53 and the GADD45a gene was investigated. The evidence presented here supports the hypothesis: in wt TK6 cells, mutation of either the p53 RE or the WT1 RE reduces the induction of a GADD45a-GFP reporter gene, whereas in p53 mutant WI-L2-NS cells, these mutations completely abrogate expression.
Protein expression is a preferred indicator of biological relevance because mRNA levels do not necessarily translate into protein levels. For GADD45a, it has been shown in mouse embryonic fibroblasts that although GADD45a transcription is increased by many different stresses, the protein accumulates only for a subset of these (24) This implies that conclusions regarding genotoxicity drawn from GADD45a induction in mRNA expression arrays alone might be unreliable compared with assays that report protein expression. In the GADD45a-GFP assay used here, fluorescence induction in control experiments is indicative of basal levels of GADD45a expression. The GADD45a gene itself is wt in both TK6 cells and p53 mutant WI-L2-NS cells (23) and there was no significant difference in basal GADD45a-driven GFP expression between the two cell lines. However, the GFP expression levels in both TK6WT1RE
− and WI-L2-NSWT1RE − cells were significantly higher than either the unmutated or p53 RE-mutated reporters (24-34%, P < 0.05) although they were not significantly different to each other (P = 0.8). This suggests that the WT1-binding site is involved in repression of GADD45a by a p53-independent mechanism. This is consistent with the finding that Myc regulation maps to the WT1-binding site in the GADD45a promoter and is a repressor of GADD45a in the absence of DNA damage. If the mutation introduced for this study inhibits the binding of WT1 and hence Myc interaction, it would be expected to relieve repression and result in a higher basal level (25) . Furthermore, on induction by DNA damage, the absence of WT1 binding would limit interactions between p53 and the promoter, resulting in lower levels of GFP. Indeed, significant reduction in induced GFP expression was observed in all reporters carrying WT1 mutations.
GADD45a induction by mechanistically diverse genotoxins was affected similarly in the different reporter-cell line/plasmid combinations. Wt cells produced the highest induction, followed by TK6 WT1RE− and then TK6 p53RE−
. This was most pronounced with the direct-acting genotoxins, suggesting that the presence of p53 at its RE is more significant than its interaction with WT1, which is perhaps not surprising given the importance of p53 in the wider response to DNA damage. These data support a model involving an induction-facilitating conformational change in GADD45a, mediated through the interaction of intron-bound p53 with promoter-bound WT1 (either through direct interaction or through an indirect interaction involving one or more other proteins). When p53 is not anchored to GADD45a at intron 3, this conformational change cannot occur and this diminishes the effect of p53 regulation. Even in the absence of bound WT1 at the promoter, there is still regulation of the GADD45a gene, which is affected by mutation at the p53 RE, suggesting that p53 anchored at intron 3 is still involved in regulation at the promoter. This might reflect p53 association with other proteins bound at the GADD45a promoter or conformational changes to chromatin structure that extend back to the promoter.
WI-L2-NS cells express dysfunctional p53 protein that has nevertheless been shown to bind to intron 3 of GADD45a (6, 23) . This work demonstrates that despite this binding, there is a deficiency in genotoxin-stimulated induction of GADD45a because in WI-L2-NS cells, GADD45a induction is severely abrogated in all reporters. This suggests that mutant p53 bound at intron 3 does not interact with WT1 at the promoter and this is consistent with other reports in which mutated p53 from WI-L2-NS cells has less effective interactions with other target proteins. The only identified mutation in WI-L2-NS p53 is a methionine-isoleucine transition at codon 237 in exon 7, which contains the DNA-binding domain (6, 23) . It might be that this domain is also involved in interactions with other DNA-binding proteins such as WT1; however, the sequence was only derived from base pairs 360-1070 in a previous study, and it is plausible that there are other mutations affecting protein-protein interactions (23). The sequences of the WT1 and p53 RE were mutated to disrupt the consensus sequences recognised by WT1 or p53. Altered DNA sequences are italicised. For most mutated reporter strains induction was either absent, or at a higher LEC than for unmutated reporter strains. LECs were calculated as the average of four independent repeats. '-' indicates a negative result. Refer to Table I for strain/plasmid information.
The differing responses between test compounds suggest variable dependence on p53 interaction with the GADD45a promoter. For direct-acting genotoxins, there were clear differences in WT1 RE mutants-MMS gave the lowest induction followed by mitomycin C (MMC) and then cisplatin. This suggests that induction in response to MMS is more dependent on the p53 promoter interaction than induction by MMC or cisplatin. The p53-dependent pathway involves the activation of ataxia telangiectasia mutated (ATM) and its subsequent phosphorylation of p53, followed by activation of p53 targets (26) . WT1 has also been shown to be involved in the ATM-mediated response (27) . Double-strand breaks resulting from MMS exposure are likely to trigger this response pathway as ATM is involved in both homologous recombination and nonhomologous end joining DSB repair pathways (16, 28) . Loss of WT1 binding from the GADD45a promoter would inhibit this pathway and induction will then depend on other pathways, most likely involving interactions of p53 with other proteins bound at the promoter. The lower dependence on WT1 observed with cisplatin and MMC is likely a reflection of induction mediated through a differing pathway. Both compounds cause cross-links (29, 30) that are likely to require first nucleotide excision repair (NER) followed by recombinational repair (31) . BRCA1 is involved in NER and is also involved in the regulation of GADD45a (26, 32, 33) . BRCA1 is also known to interact with p53, which makes it a candidate for an alternative interaction that leads to less potent induction, possibly resulting in a suboptimal conformational change (34) . Hydroxyurea and aphidicolin failed to significantly induce GFP in the mutant reporter strains, suggesting the involvement of a highly p53-and WT1-dependent pathway. Both compounds can be clastogenic, acting through formation of an inhibitory complex with DNA polymerase α and inhibition of ribonucleotide reductase, respectively (35) (36) (37) . Neither compound is DNA reactive but exposure to both results in inhibition of DNA synthesis. These compounds cause DNA damage during S phase, which triggers p53-mediated induction of several downstream genes involved in cell cycle arrest/apoptosis. If the response they provoke is strongly dependent on p53 then any alteration to the RE would result in reduced induction of genes such as GADD45a as observed in this study. In contrast, 5-fluorouracil causes irreversible inhibition of thymidylate synthase and hence precursor supply for DNA synthesis is decreased and replication stalled. It might, therefore, be expected to produce similar results to hydroxyurea and aphidicolin, although the potencies of these different agents are quite different, and this will affect the degree to which p53 protein synthesis is activated (38, 39) and the extent to which different repair activities are induced and hence the level of DNA damage signalling.
Benomyl disrupts spindle formation through suppression of dynamic microtubule instability by increasing acetylation (40, 41) . Spindle microtubules are essential for all stages of mitosis and their dynamics are crucial for progression through the cell cycle. During mitosis, the spindle microtubules bind to the kinetochores assembled at the centromere. Core spindle checkpoint proteins (Mad1, Mad2, BubR1, Bub1, Bub3 and Mps1) associate with the kinetochores early in mitosis and as such are well placed to monitor the subsequent interactions regulating attachment and dynamics (42) . Should the microtubule dynamics be adversely affected, the checkpoint will be activated and cell cycle progression halted.
Both p53 and BRCA1 involvement in the response to microtubule disruption has been proposed and this in turn suggests pathways for GADD45a induction in both wt and mutant p53 cells (40, 41, 43) . The maximal GADD45a response to benomyl was only detected with TK6 wt cells and induction did not cross the threshold in any of the mutant reporter cell lines although there were subthreshold differences between the WT1 RE mutant and the p53 RE mutant. BRCA1 has been implicated with the induction of GADD45a in response to the microtubule disruptors vincristine and taxol. After exposure to vincristine and taxol, cells were observed arrested at both G2/M and mitotic stages suggesting the involvement of both checkpoints (43) . Clearly, the p53-WT1 interaction is required for maximal induction but the induction seen with the WT1 RE mutant may be due to an interaction with BRCA1 at the GADD45a promoter rather than WT1 (34) . The required conformational change may be partially accomplished resulting in higher levels of induction than those seen without it in the p53 RE mutant.
The results from GreenScreen HC are in agreement with previously published genotoxicity data for these compounds and this study of GADD45a induction in the p53 mutant cell line adds further support to the requirement for fully functioning p53 to efficiently and effectively induce DNA damage response pathways. However, because induction is still detectable, it can be concluded that there are p53-independent pathways that induce DNA damage response pathways involving GADD45a.
This study provides genetic evidence for the requirement of interaction between WT1 and p53 proteins, bound to their respective REs in the GADD45a gene, to illicit wt levels of induction in response to both DNA damage and chromosome missegregation. It highlights the presence of alternative pathways for GADD45a activation when p53 regulation is compromised and accounts for the broad responsiveness of the GADD45a-GFP reporter assay for genotoxic stress. As well as the insight into GADD45a regulation, this research highlights the importance of using cell lines with fully functioning p53 and other repair pathways, in assays designed to assess potential human hazard (44) .
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